IL17A and psoriasis: The availability of biological agents, in particular, novel interleukins (IL) such as IL-17 and IL-23 inhibitors, has allowed dermatologists to successfully treat moderate-to-severe psoriasis, with many patients achieving clear skin [8,9,10,11,12,13] and improving their QoL [14,15,16].